Zobrazeno 1 - 10
of 42
pro vyhledávání: '"trispecific antibodies"'
Autor:
Valentina Urzì Brancati, Letteria Minutoli, Herbert Ryan Marini, Domenico Puzzolo, Alessandro Allegra
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 4603-4617 (2023)
Multiple myeloma (MM) is malignant disease characterized by the clonal proliferation of plasma cells in the bone marrow, leading to anemia, immunosuppression, and other symptoms, that is generally hard to treat. In MM, the immune system is likely exp
Externí odkaz:
https://doaj.org/article/69a7ad46e9514f30879e8c79f5c790cf
Autor:
Jinhu Liang, Linlin Zhai, Zuxin Liang, Xiaoling Chen, Yushan Jiang, Yuanlong Lin, Shiyan Feng, Yingxia Liu, Wei Zhao, Fuxiang Wang
Publikováno v:
Vaccines, Vol 12, Iss 1, p 19 (2023)
Multitudinous broadly neutralizing antibodies (bNAbs) against HIV-1 have been developed as novel antiviral prophylactic and therapeutic agents. Combinations of bNAbs are generally even more effective than when they are applied individually, showing e
Externí odkaz:
https://doaj.org/article/811d281a57b541119ee4b08389dc9e05
Autor:
Yaping Sun, Jian Xu
Publikováno v:
Advanced NanoBiomed Research, Vol 3, Iss 1, Pp n/a-n/a (2023)
Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal
Externí odkaz:
https://doaj.org/article/2c7831af5acf4ed5b3bbf5ea82c7bcaf
Autor:
Antonio Tapia-Galisteo, Íñigo Sánchez Rodríguez, Oscar Aguilar-Sopeña, Seandean Lykke Harwood, Javier Narbona, Mariola Ferreras Gutierrez, Rocío Navarro, Laura Martín-García, Cesáreo Corbacho, Marta Compte, Javier Lacadena, Francisco J. Blanco, Patrick Chames, Pedro Roda-Navarro, Luis Álvarez-Vallina, Laura Sanz
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trial
Externí odkaz:
https://doaj.org/article/50e1a9f6bc804a1eacd6d85e57eda00b
Autor:
Yamna Jadoon, Mustaqeem A. Siddiqui
Publikováno v:
Cancer Treatment and Research Communications, Vol 29, Iss , Pp 100468- (2021)
Despite available therapies, Multiple Myeloma (MM) remains an incurable hematologic malignancy. Over the past three decades, there have been tremendous developments in therapeutic options for MM. In regards to immunotherapy, Daratumumab was the first
Externí odkaz:
https://doaj.org/article/cf42d5dae5144927981c61e8120c87a9
Autor:
Stefan Warmuth, Tea Gunde, Daniel Snell, Matthias Brock, Christopher Weinert, Alexandre Simonin, Christian Hess, Julia Tietz, Maria Johansson, Fabio Mario Spiga, Robin Heiz, Naomi Flückiger, Sandro Wagen, Julia Zeberer, Dania Diem, Dana Mahler, Belinda Wickihalder, Simone Muntwiler, Bithi Chatterjee, Benjamin Küttner, Bettina Bommer, Yasemin Yaman, Peter Lichtlen, David Urech
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Co-stimulatory 4–1BB receptors on tumor-infiltrating T cells are a compelling target for overcoming resistance to immune checkpoint inhibitors, but initial clinical studies of 4–1BB agonist mAbs were accompanied by liver toxicity. We sought to en
Externí odkaz:
https://doaj.org/article/2cef15a66dc442d1a31020e1730a9800
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stefan Warmuth, Tea Gunde, Daniel Snell, Matthias Brock, Christopher Weinert, Alexandre Simonin, Christian Hess, Julia Tietz, Maria Johansson, Fabio Mario Spiga, Robin Heiz, Naomi Flückiger, Sandro Wagen, Julia Zeberer, Dania Diem, Dana Mahler, Belinda Wickihalder, Simone Muntwiler, Bithi Chatterjee, Benjamin Küttner, Bettina Bommer, Yasemin Yaman, Peter Lichtlen, David Urech
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Co-stimulatory 4–1BB receptors on tumor-infiltrating T cells are a compelling target for overcoming resistance to immune checkpoint inhibitors, but initial clinical studies of 4–1BB agonist mAbs were accompanied by liver toxicity. We sought to en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c65a392b42386048d75da1b31b47ae5
https://pubmed.ncbi.nlm.nih.gov/35844969
https://pubmed.ncbi.nlm.nih.gov/35844969
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.